Business Context and Reporting Period
Company: GlaxoSmithKline plc
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: December 28, 2005
Context: The registrant notified the SEC of an application to the UK Listing Authority and the London Stock Exchange for block listings of new ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding share issuance rather than a financial results report.
Material Changes
The primary material event is the proposed issuance of 20,390,000 Ordinary shares of 25p each. These shares will rank pari passu with existing issued shares. The breakdown of the block listings is as follows:
- 10,000,000 shares under the GlaxoSmithKline Share Option Plan
- 140,000 shares under the Glaxo Group Share Option Scheme
- 10,000,000 shares under the GlaxoSmithKline Savings Related Option Scheme
- 250,000 shares under the SmithKline Beecham 1989 Executive Share Option Plan-Unapproved-Ordinary shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the administrative process of listing the new shares on the London Stock Exchange and admitting them to the Official List upon issuance.
Investor Verification Checklist
- Verify the final admission of the 20,390,000 shares to the Official List of the London Stock Exchange.
- Confirm the specific vesting schedules and exercise terms for the four distinct share option plans mentioned.
- Review subsequent filings for the actual issuance date and any dilution impact on existing shareholders.